Literature DB >> 9161109

Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer. The Study Group on Quality of Life of the EORTC and the Symptom Control and Quality of Life Committees of the NCI of Canada Clinical Trials Group.

D Osoba1, N Aaronson, B Zee, M Sprangers, A te Velde.   

Abstract

A revision of the Quality of Life Questionnaire (QLQ-C30) of the European Organization for Research and Treatment of Cancer (EORTC) was undertaken to improve low internal consistency estimates (Cronbach's alpha) and content validity for the role functioning scale and a conceptual difficulty (undue emphasis on physical functioning) in the global quality of life (QOL) scale. The role functioning items were reworded and a four-category response format was substituted for the previous dichotomous format. A new item asking about 'overall health' was substituted for the 'overall physical condition' item in the global QOL domain. The original and new versions were tested at three time points in a total of 1,181 patients with cancer in Canada (n = 696) and the Netherlands (n = 485). In both samples there was a marked improvement in internal consistency for the role functioning scale (Cronbach's alpha s ranging from 0.78-0.88) in the new version. In the global QOL scale, the substitution of the new item for the previous one did not alter internal consistency (Cronbach's alpha's ranging from 0.81-0.92). The revised versions of the role functioning and global QOL domains have been incorporated into the QLQ-C30 (version 2.0).

Entities:  

Mesh:

Year:  1997        PMID: 9161109     DOI: 10.1023/a:1026429831234

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  9 in total

1.  The EORTC core quality of life questionnaire (QLQ-C30): validity and reliability when analysed with patients treated with palliative radiotherapy.

Authors:  S Kaasa; K Bjordal; N Aaronson; T Moum; E Wist; S Hagen; A Kvikstad
Journal:  Eur J Cancer       Date:  1995-12       Impact factor: 9.162

2.  Test for item bias in a quality of life questionnaire.

Authors:  M Groenvold; J B Bjorner; M C Klee; S Kreiner
Journal:  J Clin Epidemiol       Date:  1995-06       Impact factor: 6.437

3.  Psychometric validation of the EORTC Core Quality of Life Questionnaire, 30-item version and a diagnosis-specific module for head and neck cancer patients.

Authors:  K Bjordal; S Kaasa
Journal:  Acta Oncol       Date:  1992       Impact factor: 4.089

4.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.

Authors:  N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes
Journal:  J Natl Cancer Inst       Date:  1993-03-03       Impact factor: 13.506

5.  Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer.

Authors:  D Osoba; B Zee; J Pater; D Warr; L Kaizer; J Latreille
Journal:  Qual Life Res       Date:  1994-10       Impact factor: 4.147

6.  Test/retest study of the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire.

Authors:  M J Hjermstad; S D Fossa; K Bjordal; S Kaasa
Journal:  J Clin Oncol       Date:  1995-05       Impact factor: 44.544

7.  A validation study of the domains of the core EORTC quality of life questionnaire.

Authors:  H E Niezgoda; J L Pater
Journal:  Qual Life Res       Date:  1993-10       Impact factor: 4.147

8.  Testing the EORTC Quality of Life Questionnaire on cancer patients with heterogeneous diagnoses.

Authors:  G I Ringdal; K Ringdal
Journal:  Qual Life Res       Date:  1993-04       Impact factor: 4.147

9.  The Karnofsky Performance Status Scale re-examined: a cross-validation with the EORTC-C30.

Authors:  J Schaafsma; D Osoba
Journal:  Qual Life Res       Date:  1994-12       Impact factor: 4.147

  9 in total
  50 in total

1.  Effect of neurological dysfunction on health-related quality of life in patients with high-grade glioma.

Authors:  D Osoba; N K Aaronson; M Muller; K Sneeuw; M A Hsu; W K Yung; M Brada; E Newlands
Journal:  J Neurooncol       Date:  1997-09       Impact factor: 4.130

2.  Early stage breast cancer: explaining level of psychosocial adjustment using structural equation modeling.

Authors:  Petra J Vos; Bert Garssen; Adriaan P Visser; Hugo J Duivenvoorden; Hanneke C J M de Haes
Journal:  J Behav Med       Date:  2004-12

3.  The use of differential item functioning analyses to identify cultural differences in responses to the EORTC QLQ-C30.

Authors:  N W Scott; P M Fayers; N K Aaronson; A Bottomley; A de Graeff; M Groenvold; M Koller; M A Petersen; M A G Sprangers
Journal:  Qual Life Res       Date:  2006-11-16       Impact factor: 4.147

4.  A prospective longitudinal clinical trial evaluating quality of life after breast-conserving surgery and high-dose-rate interstitial brachytherapy for early-stage breast cancer.

Authors:  Adam A Garsa; Daniel J Ferraro; Todd A DeWees; Teresa L Deshields; Julie A Margenthaler; Amy E Cyr; Michael Naughton; Rebecca Aft; William E Gillanders; Timothy Eberlein; Melissa A Matesa; Laura L Ochoa; Imran Zoberi
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-10-22       Impact factor: 7.038

5.  Assessing the consistency of psychometric properties of the HRQoL scales within the EORTC QLQ-C30 across populations by means of the Mokken Scaling Model.

Authors:  K Ringdal; G I Ringdal; S Kaasa; K Bjordal; F Wisløff; S Sundstrøm; M J Hjermstad
Journal:  Qual Life Res       Date:  1999       Impact factor: 4.147

6.  Exercise in patients receiving hematopoietic stem cell transplantation: lessons learned and results from a feasibility study.

Authors:  Eileen Danaher Hacker; Janet L Larson; David Peace
Journal:  Oncol Nurs Forum       Date:  2011-03       Impact factor: 2.172

7.  Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study.

Authors:  D Schadendorf; M M Amonkar; M Milhem; K Grotzinger; L V Demidov; P Rutkowski; C Garbe; R Dummer; J C Hassel; P Wolter; P Mohr; U Trefzer; C Lefeuvre-Plesse; A Rutten; N Steven; G Ullenhag; L Sherman; F S Wu; K Patel; M Casey; C Robert
Journal:  Ann Oncol       Date:  2014-02-06       Impact factor: 32.976

8.  Validity, reliability and clinical relevance of EORTC QLQ-C30 and LC13 in patients with chest malignancies in a palliative setting.

Authors:  Mercedes Nicklasson; Bengt Bergman
Journal:  Qual Life Res       Date:  2007-05-04       Impact factor: 4.147

9.  Distress screening remains important during follow-up after primary breast cancer treatment.

Authors:  Floortje K Ploos van Amstel; Sanne W van den Berg; Hanneke W M van Laarhoven; Marieke F M Gielissen; Judith B Prins; Petronella B Ottevanger
Journal:  Support Care Cancer       Date:  2013-03-01       Impact factor: 3.603

10.  Effects of mode of administration (MOA) on the measurement properties of the EORTC QLQ-C30: a randomized study.

Authors:  Chad M Gundy; Neil K Aaronson
Journal:  Health Qual Life Outcomes       Date:  2010-03-30       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.